Literature DB >> 21518924

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

René-Olivier Casasnovas1, Michel Meignan, Alina Berriolo-Riedinger, Stéphane Bardet, Anne Julian, Catherine Thieblemont, Pierre Vera, Serge Bologna, Josette Brière, Jean-Philippe Jais, Corinne Haioun, Bertrand Coiffier, Franck Morschhauser.   

Abstract

The prognostic value of interim positron emission tomography (PET) interpreted according to visual criteria is a matter of debate in diffuse large B-cell lymphoma (DLBCL). Maximal standardized uptake value reduction (ΔSUVmax) may better predict outcome. To compare the prognostic value of both methods, we analyzed PET done at baseline (PET0) and after 2 (PET2) and 4 (PET4) cycles in 85 patients with high-risk DLBCL enrolled on a prospective multicenter trial. All images were centrally reviewed and interpreted visually according to the International Harmonization Project criteria and by computing ΔSUVmax between PET0 and PET2 (ΔSUVmaxPET0-2) or PET4 (ΔSUVmaxPET0-4). Optimal cutoff to predict progression or death was 66% for ΔSUVmaxPET0-2 and 70% for ΔSUVmaxPET0-4. Outcomes did not differ significantly whether PET2 and PET4 were visually positive or negative. Inversely, ΔSUVmaxPET0-2 analysis (> 66% vs ≤ 66%) identified patients with significantly different 2-year progression-free survival (77% vs 57%; P = .0282) and overall survival (93% vs 60%; P < .0001). ΔSUVmaxPET0-4 analysis (> 70% vs ≤ 70%) seemed even more predictive for 2-year progression-free survival (83 vs 40%; P < .0001) and overall survival (94% vs 50%; P < .0001). ΔSUVmax analysis of sequential interim PET is feasible for high-risk DLBCL and better predicts outcome than visual analysis. The trial was registered at http://clinicaltrials.gov as NCT00498043.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518924     DOI: 10.1182/blood-2010-12-327767

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  73 in total

Review 1.  Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?

Authors:  Rene-Olivier Casasnovas; Michel Meignan; Alina Berriolo-Riedinger; Emmanuel Itti; Damien Huglo; Corinne Haioun; Franck Morschhauser
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

2.  Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.

Authors:  Heiko Schöder; Andrew D Zelenetz; Paul Hamlin; Somali Gavane; Steven Horwitz; Matthew Matasar; Alison Moskowitz; Ariela Noy; Lia Palomba; Carol Portlock; David Straus; Ravinder Grewal; Jocelyn C Migliacci; Steven M Larson; Craig H Moskowitz
Journal:  J Nucl Med       Date:  2015-12-30       Impact factor: 10.057

3.  Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Authors:  Mark Hertzberg; Maher K Gandhi; Judith Trotman; Belinda Butcher; John Taper; Amanda Johnston; Devinder Gill; Shir-Jing Ho; Gavin Cull; Keith Fay; Geoff Chong; Andrew Grigg; Ian D Lewis; Sam Milliken; William Renwick; Uwe Hahn; Robin Filshie; George Kannourakis; Anne-Marie Watson; Pauline Warburton; Andrew Wirth; John F Seymour; Michael S Hofman; Rodney J Hicks
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

4.  Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.

Authors:  Dong Won Baek; Hee Jeong Cho; Ju-Hyung Kim; Sang Kyun Sohn; Ga-Young Song; Seo-Yeon Ahn; Sung-Hoon Jung; Jae Sook Ahn; Je-Jung Lee; Hyeoung-Joon Kim; Shin-Young Jeong; Chae Moon Hong; Jung-Joon Min; Joon-Ho Moon; Deok-Hwan Yang
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 5.  The evolving role of response-adapted PET imaging in Hodgkin lymphoma.

Authors:  Michael Coyle; Lale Kostakoglu; Andrew M Evens
Journal:  Ther Adv Hematol       Date:  2016-04

Review 6.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 7.  FDG PET/CT imaging as a biomarker in lymphoma.

Authors:  Michel Meignan; Emmanuel Itti; Andrea Gallamini; Anas Younes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

Review 8.  Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography.

Authors:  Michel Meignan; Martin Hutchings; Lawrence H Schwartz
Journal:  Oncologist       Date:  2015-07-14

9.  FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?

Authors:  Josée M Zijlstra; Coreline N Burggraaff; Marie José Kersten; Sally F Barrington
Journal:  Haematologica       Date:  2016-11       Impact factor: 9.941

10.  Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Chiara Pagani; Alessandro Re; Alessandra Tucci; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.